NYMC Faculty Publications

The Preclinical Profile of Brexpiprazole: What is its Clinical Relevance for the Treatment of Psychiatric Disorders?

Author Type(s)

Faculty

DOI

10.1586/14737175.2015.1086269

Journal Title

Expert Review of Neurotherapeutics

First Page

1219

Last Page

1229

Document Type

Article

Publication Date

10-1-2015

Department

Psychiatry and Behavioral Sciences

Keywords

Animals, Clinical Trials, Phase III as Topic, Drug Evaluation, Preclinical, Humans, Mental Disorders, Quinolones, Randomized Controlled Trials as Topic, Thiophenes

Disciplines

Medicine and Health Sciences

Abstract

Brexpiprazole is a serotonin-dopamine activity modulator in clinical development for schizophrenia, adjunctive treatment of major depressive disorder, agitation in Alzheimer's disease and post-traumatic stress disorder. It is a partial agonist at 5-HT1A and D2 receptors with similar potency, and an antagonist at 5-HT2A and adrenergic α1B/2C receptors. Compared with aripiprazole, brexpiprazole is more potent at 5-HT1A receptors and displays less intrinsic activity at D2 receptors. This unique serotonin and dopamine modulatory activity has shown robust antipsychotic, antidepressant-like and anxiolytic activities, and limited extrapyramidal symptom liability with pro-cognitive efficacy in animal models. Phase III clinical trials have been successfully completed in schizophrenia and adjunctive use in major depressive disorder, with the US FDA approval obtained for these uses; Phase III studies in Alzheimer's disease and post-traumatic stress disorder are ongoing.

Link to Full Text

Share

COinS